<DOC>
	<DOCNO>NCT00408434</DOCNO>
	<brief_summary>An open-label , Phase I , dose escalation study CS-7017 administer mouth sequential cohort 3 6 patient advanced metastatic malignancy .</brief_summary>
	<brief_title>Study Experimental New Drug , PPAR Agonist Taken Mouth Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<criteria>Histologically cytologically diagnose advanced metastatic malignancy refractory , curable , eligible standard treatment ( ) . 18 year old ECOG performance status less equal 2 . Resolution toxic effect prior therapy ( except alopecia ) NCI CTCAE v3.0 grade le equal 1 . Adequate organ bone marrow function . Willing use effective contraceptive treatment least 3 month thereafter . Negative pregnancy test female childbearing potential . Echocardiogram EF within normal range . Anticipation need major surgical procedure radiation therapy study . Treatment chemotherapy , hormonal therapy , TZDs , radiotherapy , minor surgery , investigational agent within 4 wks ( 6 wks nitrosoureas , mitomycin C , immunotherapy , biological therapy , major surgery ) study treatment start . Patients clinically significant pleural pericardial effusion ( patient minimal pleural effusion may eligible Investigator 's discretion ) . Clinically significant active infection , require antibiotic therapy , HIVpositive patient receive antiretroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>PPARgamma agonist</keyword>
	<keyword>advanced metastatic malignancy</keyword>
	<keyword>Tumor</keyword>
	<keyword>Cancer</keyword>
</DOC>